<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740166</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS13-CT6-06</org_study_id>
    <nct_id>NCT02740166</nct_id>
  </id_info>
  <brief_title>Preventing Recurrent Bleeding After Eradication of Esophageal Varices</brief_title>
  <official_title>Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophageal variceal bleeding is a severe complication of portal hypertension. Banding
      ligation plus non-selective beta-blockers is the current recommendation for prevention of
      recurrent bleeding. However, the optimal duration of use of non-selective beta-blockers is
      not well defined. This study aims at comparing the rebleeding rate and adverse effects in
      patients using or without using propranolol after eradication of esophageal varices.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhotic patients with acute or recent esophageal variceal bleeding undergo banding ligation
      at 1-month interval until eradication of esophageal varices. Patients start propranolol
      (start with 30 mg daily) at 6th day after control of acute bleeding till eradication of
      esophageal varices, aiming at decreasing pulse rate to 25% or to 55 bpm while systolic
      pressure is above 85 mmHg. Patients randomized to propranolol group continue propranolol
      after eradication of esophageal varices. Patients randomized to banding ligation group
      discontinue propranolol after eradication of esophageal varices. Patients are followed to
      evaluate the incidence of rebleeding, adverse effects and survival.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrent esophageal variceal bleeding</measure>
    <time_frame>6 years</time_frame>
    <description>recurrent esophageal variceal bleeding after eradication of esophageal varices</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality or liver transplantation</measure>
    <time_frame>6 years</time_frame>
    <description>mortality or liver transplantation after eradication of esophageal varices</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>6 years</time_frame>
    <description>adverse effects associated with non-selective beta-blockers and banding ligation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Esophageal Varices</condition>
  <arm_group>
    <arm_group_label>Banding ligation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.</description>
    <arm_group_label>Propranolol group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 20 to 80 years

          -  Cirrhotic patients with acute or recent esophageal variceal bleeding proven by an
             endoscopy

          -  Stable hemodynamic condition for at least 3 days after banding ligation

        Exclusion Criteria:

          -  Hepatocellular carcinoma or other malignancy

          -  Stroke or active sepsis

          -  Chronic kidney disease under renal replacement therapy

          -  Contraindications to non-selective beta-blockers

          -  A history of non-selective beta-blockers use, sclerotherapy, banding ligation,
             transjugular intrahepatic porto-systemic shunt, or shunt surgery

          -  Serum total bilirubin &gt;10 mg/dL

          -  Grade III/IV hepatic encephalopathy

          -  Refractory ascites

          -  Hepato-renal syndrome

          -  Pregnancy

          -  Severe heart failure (NYHA Fc III/IV)

          -  Bronchial asthma or chronic obstructive pulmonary disease

          -  Second or third degree atrioventricular block

          -  Sick sinus syndrome

          -  Pacemaker use

          -  Severe hypotension

          -  Refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Chi Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wen-Chi Chen, MD</last_name>
    <phone>886-7-3422121</phone>
    <phone_ext>2139</phone_ext>
    <email>wcchen@vghks.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Chi Chen, MD</last_name>
      <phone>+886-7-3422121</phone>
      <phone_ext>2139</phone_ext>
      <email>wcchen@vghks.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Wen-Chi Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Gonzalez R, Zamora J, Gomez-Camarero J, Molinero LM, Ba침ares R, Albillos A. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008 Jul 15;149(2):109-22.</citation>
    <PMID>18626050</PMID>
  </reference>
  <reference>
    <citation>Lo GH, Lai KH, Cheng JS, Chen MH, Huang HC, Hsu PI, Lin CK. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology. 2000 Sep;32(3):461-5.</citation>
    <PMID>10960435</PMID>
  </reference>
  <reference>
    <citation>de la Pe침a J, Brullet E, Sanchez-Hern치ndez E, Rivero M, Vergara M, Martin-Lorente JL, Garcia Su치rez C. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology. 2005 Mar;41(3):572-8.</citation>
    <PMID>15726659</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Jha SK, Sharma P, Dubey S, Tyagi P, Sharma BC, Sarin SK. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology. 2009 Sep;137(3):892-901, 901.e1. doi: 10.1053/j.gastro.2009.05.049. Epub 2009 May 27.</citation>
    <PMID>19481079</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Wen-Chi Chen</investigator_full_name>
    <investigator_title>Division of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <keyword>Esophageal Varices; propranolol; banding ligation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

